Abstract: Background Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death.
Abstract: Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death.
Abstract: Aims The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac ...
Abstract: Background Lipoprotein(a) concentration is associated with cardiovascular events.
... patients with acute coronary syndromes undergoing early percutaneous coro- nary intervention: results of the ARMYDA- ACS randomized trial ... syndrome receiving loading doses of atorvastatin prior to planned PCI. JAMA. 2020;323(8):787–789 ...
... trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809-19. 22. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease ... Polyvascular disease, type 2 diabetes, and ...
From basic science to pathogenesis of atherothrombotic disease, to risk assessment and the latest therapy options, this medical reference book offers unparalleled coverage and expert guidance on lipidology in a straightforward, accessible, ...
... patients with peripheral arterial disease: a case- control study. Front Cardiovasc Med. 2017;4:23. Available from: https://doi.org/ 10.3389/fcvm.2017.00023. 22. Hiatt WR, Fowkes FG, Heizer G ... disease. and. the. cardiometabolic. syndrome.
... Outcomes Trials . Front Cardiovasc Med 2019 ; 6:14 . 70. Jukema JW , Szarek M , Zijlstra LE , et al . Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome : ODYSSEY OUTCOMES Trial ... patients with peripheral ...
... Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2019;74:1167-76. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A ...